Search
Close this search box.

Cystic Fibrosis

VX18-445-109

STUDY OUTLINE

The study aims to evaluate the efficacy and safety of VX-445/tezacaftor/ivacaftor in Cystic Fibrosis patients homozygous for F508del (F/F).

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged 18 or over with a diagnosis of Cystic Fibrosis and an F/F genotype.
  • FEV1 between 40% and 90% predicted.
  • No History of organ transplantation.
  • Not pregnant or breastfeeding.

WHAT'S INVOLVED

  • The total study duration is approximately 36 weeks (4 weeks for the Screening Period, 4 weeks for the TEZ/IVA Run-in Period, 24 weeks for the Treatment Period, and 4 weeks for the Safety Follow-up Period).
  • It involves up to 10 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and up to 2 phone calls.

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top